The Fast Follower’s Prize

GLP-1 drugs, the weight-loss and diabetes medicines that became a global phenomenon, are the richest prize in pharmaceuticals, and China is coming at them from two directions at once. It is developing its own, and preparing to copy everyone else’s.

On the innovation side, Innovent won approval from China’s regulator in mid-2025 for mazdutide, billed as the world’s first dual GCG/GLP-1 receptor agonist cleared for weight management, followed by a diabetes approval that autumn.^[1][2] In a late-stage trial its top dose cut body weight by about 15%.^[1] The market it serves is vast: more than 500 million Chinese adults are overweight or obese, and some 148 million have diabetes.^[1]

China is developing its own GLP-1s and preparing to copy everyone else’s. The patent cliff and the innovation push arrive in the same year.

The cliff and the licence

The copying opportunity is enormous and imminent. Semaglutide, the molecule behind Ozempic and Wegovy, loses its core patent protection in China in March 2026, and around sixteen domestic companies are already developing generic or biosimilar versions, several filed as new small-molecule drugs to lower the regulatory bar.^[4] Chinese generics have historically priced roughly 80% below the branded original. Meanwhile the assets flow west too: Hengrui licensed its GLP-1 portfolio to a US “NewCo”, $110 million upfront against billions in milestones and a near-20% equity stake, that raised $400 million to launch.^[3]

Two honest notes. Mazdutide’s molecule was originally licensed from Eli Lilly, so it is a Chinese development-and-commercialisation success more than a pure origination. And as of the patent expiry no Chinese semaglutide generic had yet been approved; the flood is queued, not yet flowing.

What we do with this

GLP-1 is the perfect stage for China’s two-track model: fast-follow the blockbuster to serve a colossal domestic market at a fraction of the price, and license the genuinely novel assets to Western partners with the capital to run global trials. For investors that splits the opportunity cleanly, volume and price at home, deal value abroad, and it makes the March 2026 patent cliff a live test of how quickly China’s copiers can move. The prize is real on both tracks; the discipline is to value the domestic generic wave and the out-licensed innovation on entirely different logics.